{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:10:48Z","timestamp":1793729448682,"version":"4.6.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["H-154-00-000019"],"award-info":[{"award-number":["H-154-00-000019"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University, Taiwan","doi-asserted-by":"crossref","award":["A-0001574"],"award-info":[{"award-number":["A-0001574"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science and Technology Council, Taiwan","award":["NSTC 112-2314-B-038-134"],"award-info":[{"award-number":["NSTC 112-2314-B-038-134"]}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-038-107-MY3"],"award-info":[{"award-number":["NSTC 114-2314-B-038-107-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09105-7","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T01:48:39Z","timestamp":1760665719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["PD-1\/PD-L1 Cancer Immunotherapeutics Reshape Tumor Microenvironment \u2013 Clinical Evidence and Molecular Mechanisms for AI-based Precision Medicine"],"prefix":"10.1007","volume":"68","author":[{"given":"Yen-Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeak Ling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsieh-Tsung","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeline Clarissa","family":"Adhidjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"9105_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121909","author":"J Chen","year":"2019","unstructured":"Chen J, Liu H, Jehng T, Li Y, Chen Z, Lee KD et al (2019) A novel anti-PD-L1 vaccine for cancer immunotherapy and immunoprevention. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11121909","journal-title":"Cancers (Basel)"},{"issue":"1","key":"9105_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y et al (2022) Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 15(1):24. https:\/\/doi.org\/10.1186\/s13045-022-01242-2","journal-title":"J Hematol Oncol"},{"issue":"9","key":"9105_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100532","volume":"4","author":"EB Ulas","year":"2023","unstructured":"Ulas EB, Hashemi SMS, Houda I, Kaynak A, Veltman JD, Fransen MF et al (2023) Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC. JTO Clin Res Rep 4(9):100532. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100532","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"9105_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"J-Y Sun","year":"2020","unstructured":"Sun J-Y, Zhang D, Wu S, Xu M, Zhou X, Lu X-J et al (2020) Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 8(1):35. https:\/\/doi.org\/10.1186\/s40364-020-00212-5","journal-title":"Biomark Res"},{"issue":"1","key":"9105_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1144-6","volume":"19","author":"D Ren","year":"2020","unstructured":"Ren D, Hua Y, Yu B, Ye X, He Z, Li C et al (2020) Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer 19(1):19. https:\/\/doi.org\/10.1186\/s12943-020-1144-6","journal-title":"Mol Cancer"},{"issue":"6371","key":"9105_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"issue":"2","key":"9105_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL et al (2022) Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol 17(2):206\u2013216. https:\/\/doi.org\/10.1038\/s41565-021-01032-w","journal-title":"Nat Nanotechnol"},{"issue":"22","key":"9105_CR8","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.Can-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Li CW, Lai YJ, Hung MC (2018) Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res 78(22):6349\u20136353. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-1892","journal-title":"Cancer Res"},{"issue":"6371","key":"9105_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"9105_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y (2020) Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol 8:672. https:\/\/doi.org\/10.3389\/fcell.2020.00672","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"9105_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473\u2013486. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat Rev Clin Oncol"},{"key":"9105_CR12","unstructured":"Gerriets JPFV (2023) Pembrolizumab. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546616\/. Accessed 17 Jan 2025"},{"key":"9105_CR13","unstructured":"Rayi ARA (2024) Nivolumab. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567801\/. Accessed 17 Jan 2025"},{"key":"9105_CR14","unstructured":"FDA\u2019s Division of Drug Information, FsOCoE (2022) FDA D.I.S.C.O. Burst Edition: FDA approval of Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-libtayo-cemiplimab-rwlc-combination-platinum-based-chemotherapy. Accessed 17 Jan 2025"},{"key":"9105_CR15","unstructured":"Administration tFaD (2023) FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer. Accessed 17 Jan 2025"},{"key":"9105_CR16","unstructured":"Administration tFaD (2023) FDA approves toripalimab-tpzi for nasopharyngeal carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinoma. Accessed 17 Jan 2025"},{"key":"9105_CR17","unstructured":"Administration USFaD (2024) TEVIMBRA (tislelizumab-jsgr) Prescribing Information"},{"key":"9105_CR18","unstructured":"FDA\u2019s Division of Drug Information FsOCoE (2023) FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-tecentriq-atezolizumab-unresectable-or-metastatic-alveolar. Accessed 17 Jan 2025"},{"key":"9105_CR19","unstructured":"Administration tFaD (2020) FDA approves avelumab for urothelial carcinoma maintenance treatment. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed 17 Jan 2025"},{"issue":"12","key":"9105_CR20","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY (2017) Durvalumab: first global approval. Drugs 77(12):1369\u20131376. https:\/\/doi.org\/10.1007\/s40265-017-0782-5","journal-title":"Drugs"},{"key":"9105_CR21","unstructured":"Administration tFaD (2024) FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma. Accessed 18 Jan 2025"},{"issue":"21","key":"9105_CR22","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"9105_CR23","unstructured":"Party MSDLR (2023) Study of pembrolizumab (MK-3475) versus platinum-based chemotherapy for participants with programmed cell death-ligand 1 (PD-L1)-positive advanced or metastatic non-small cell lung cancer (MK-3475-042\/KEYNOTE-042). https:\/\/clinicaltrials.gov\/study\/NCT02220894?tab=results. Accessed 17 Jan 2025"},{"issue":"10027","key":"9105_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"1","key":"9105_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/cco.0000000000000700","volume":"33","author":"R Pirker","year":"2021","unstructured":"Pirker R (2021) Immunotherapy combinations in advanced nonsmall cell lung cancer. Curr Opin Oncol 33(1):73\u201379. https:\/\/doi.org\/10.1097\/cco.0000000000000700","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"9105_CR26","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K et al (2022) Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 28(11):2374\u20132380. https:\/\/doi.org\/10.1038\/s41591-022-01977-y","journal-title":"Nat Med"},{"key":"9105_CR27","unstructured":"The Surveillance E, and End Results (SEER) Program (2025). Cancer stat facts: common cancer sites. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html. Accessed 17 Jan 2025"},{"key":"9105_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2016.11.003","volume":"108","author":"SC Chang","year":"2016","unstructured":"Chang SC, Yang WV (2016) Hyperglycemia, tumorigenesis, and chronic inflammation. Crit Rev Oncol Hematol 108:146\u2013153. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.11.003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"9105_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li T, Zhang H, Lian M, He Q, Lv M, Zhai L et al (2025) Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol 18(1):5. https:\/\/doi.org\/10.1186\/s13045-025-01660-y","journal-title":"J Hematol Oncol"},{"issue":"20","key":"9105_CR30","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1002\/cam4.4236","volume":"10","author":"Y Ouyang","year":"2021","unstructured":"Ouyang Y, Liu W, Zhang N, Yang X, Li J, Long S (2021) Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: a systematic review and meta-analysis. Cancer Med 10(20):7021\u20137039. https:\/\/doi.org\/10.1002\/cam4.4236","journal-title":"Cancer Med"},{"key":"9105_CR31","unstructured":"ClinicalTrials.gov (2020). Study of pembrolizumab (MK-3475) monotherapy for metastatic triple-negative breast cancer (MK-3475-086\/KEYNOTE-086). https:\/\/clinicaltrials.gov\/study\/NCT02447003. Accessed 17 Jan 2025"},{"key":"9105_CR32","unstructured":"Party MSDLR (2021) Study of single agent pembrolizumab (MK-3475) versus single agent chemotherapy for metastatic triple negative breast cancer (MK-3475-119\/KEYNOTE-119). https:\/\/clinicaltrials.gov\/study\/NCT02555657. Accessed 17 Jan 2025"},{"issue":"1","key":"9105_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/cji.0000000000000489","volume":"47","author":"A Charifa","year":"2024","unstructured":"Charifa A, Lam A, Zhang H, Ip A, Pecora A, Waintraub S et al (2024) Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms. J Immunother 47(1):10\u201315. https:\/\/doi.org\/10.1097\/cji.0000000000000489","journal-title":"J Immunother"},{"key":"9105_CR34","doi-asserted-by":"publisher","unstructured":"Kim H, Kim S, Choi S, Park C, Park S, Pereira S et al (2024) Clinical validation of artificial intelligence\u2013powered PD-L1 tumor proportion score interpretation for immune checkpoint inhibitor response prediction in non\u2013small cell lung cancer. JCO Precis Oncol (8)\u00a0:e2300556. https:\/\/doi.org\/10.1200\/po.23.00556","DOI":"10.1200\/po.23.00556"},{"issue":"2","key":"9105_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","volume":"11","author":"M Rakaee","year":"2025","unstructured":"Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F et al (2025) Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer. JAMA Oncol 11(2):109\u2013118. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5356","journal-title":"JAMA Oncol"},{"key":"9105_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050714","author":"A Gschwind","year":"2025","unstructured":"Gschwind A, Ossowski S (2025) AI model for predicting anti-PD1 response in melanoma using multi-omics biomarkers. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17050714","journal-title":"Cancers (Basel)"},{"key":"9105_CR37","unstructured":"Party H-LRR (2024) A study of atezolizumab and paclitaxel versus placebo and paclitaxel in participants with previously untreated locally advanced or metastatic triple negative breast cancer (TNBC) (IMpassion131). https:\/\/clinicaltrials.gov\/study\/NCT03125902. Accessed 17 Jan 2025"},{"key":"9105_CR38","unstructured":"Party H-LRR (2022) A study of atezolizumab in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for participants with previously untreated metastatic triple-negative breast cancer (IMpassion130). https:\/\/clinicaltrials.gov\/study\/NCT02425891. Accessed 17 Jan 2025"},{"key":"9105_CR39","unstructured":"Party H-LRR (2023) A study of cobimetinib plus paclitaxel, cobimetinib plus atezolizumab plus paclitaxel, or cobimetinib plus atezolizumab plus nab-paclitaxel as initial treatment for participants with triple-negative breast cancer that has spread. https:\/\/clinicaltrials.gov\/study\/NCT02322814. Accessed 17 Jan 2025"},{"key":"9105_CR40","unstructured":"Tesaro IRP (2022) Niraparib in combination with pembrolizumab in patients with triple-negative breast cancer or ovarian cancer (TOPACIO). https:\/\/clinicaltrials.gov\/study\/NCT02657889. Accessed 17 Jan 2025"},{"key":"9105_CR41","unstructured":"Party H-LRR (2021) A study of atezolizumab in combination with carboplatin plus (+) nab-paclitaxel compared with carboplatin+nab-paclitaxel in participants with stage IV non-squamous non-small cell lung cancer (NSCLC) (IMpower130). https:\/\/clinicaltrials.gov\/study\/NCT02367781?tab=results. Accessed 17 Jan 2025"},{"issue":"7","key":"9105_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cllc.2022.07.001","volume":"23","author":"F Ardeshir-Larijani","year":"2022","unstructured":"Ardeshir-Larijani F, Althouse SK, Leal T, Feldman LE, Hejleh TA, Patel M et al (2022) A phase II trial of Atezolizumab plus Carboplatin plus Pemetrexed plus Bevacizumab in the treatment of patients with stage IV non-squamous non-small cell lung cancer: big ten cancer research consortium (BTCRC)- LUN 17\u2013139. Clin Lung Cancer 23(7):578\u2013584. https:\/\/doi.org\/10.1016\/j.cllc.2022.07.001","journal-title":"Clin Lung Cancer"},{"key":"9105_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab293","author":"B G\u00fcven\u00e7 Paltun","year":"2021","unstructured":"G\u00fcven\u00e7 Paltun B, Kaski S, Mamitsuka H (2021) Machine learning approaches for drug combination therapies. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab293","journal-title":"Brief Bioinform"},{"key":"9105_CR44","doi-asserted-by":"publisher","first-page":"153303382412759","DOI":"10.1177\/15330338241275947","volume":"23","author":"CT Ford","year":"2024","unstructured":"Ford CT (2024) PD-1 targeted antibody discovery using AI protein diffusion. Technol Cancer Res Treat 23:15330338241275948. https:\/\/doi.org\/10.1177\/15330338241275947","journal-title":"Technol Cancer Res Treat"},{"issue":"Pt 2","key":"9105_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127911","volume":"254","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Wang H, Li J, Jiang X, Li Z, Shen J (2024) Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: a review. Int J Biol Macromol 254(Pt 2):127911. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.127911","journal-title":"Int J Biol Macromol"},{"key":"9105_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55110723","author":"I Calik","year":"2019","unstructured":"Calik I, Calik M, Turken G, Ozercan IH, Dagli AF, Artas G et al (2019) Intratumoral cytotoxic T-lymphocyte density and PD-L1 expression are prognostic biomarkers for patients with colorectal cancer. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina55110723","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"9105_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152802","volume":"216","author":"X Wang","year":"2020","unstructured":"Wang X, Liu Y (2020) PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathol Res Pract 216(3):152802. https:\/\/doi.org\/10.1016\/j.prp.2019.152802","journal-title":"Pathol Res Pract"},{"issue":"1","key":"9105_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06430-1","volume":"12","author":"J Fierro","year":"2022","unstructured":"Fierro J, DiPasquale J, Perez J, Chin B, Chokpapone Y, Tran AM et al (2022) Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization. Sci Rep 12(1):2417. https:\/\/doi.org\/10.1038\/s41598-022-06430-1","journal-title":"Sci Rep"},{"key":"9105_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","author":"S-K Yoo","year":"2025","unstructured":"Yoo S-K, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES et al (2025) Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03398-5","journal-title":"Nat Med"},{"issue":"7","key":"9105_CR50","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.Can-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y et al (2019) Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res 79(7):1493\u20131506. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3208","journal-title":"Cancer Res"},{"issue":"7655","key":"9105_CR51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN et al (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495\u2013499. https:\/\/doi.org\/10.1038\/nature22396","journal-title":"Nature"},{"issue":"5","key":"9105_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR t cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471\u2013482. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006","journal-title":"Cancer Cell"},{"issue":"1","key":"9105_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/imm.13126","volume":"159","author":"H Hassannia","year":"2020","unstructured":"Hassannia H, Ghasemi Chaleshtari M, Atyabi F, Nosouhian M, Masjedi A, Hojjat-Farsangi M et al (2020) Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine. Immunology 159(1):75\u201387. https:\/\/doi.org\/10.1111\/imm.13126","journal-title":"Immunology"},{"issue":"1","key":"9105_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y et al (2020) PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 11(1):4835. https:\/\/doi.org\/10.1038\/s41467-020-18570-x","journal-title":"Nat Commun"},{"issue":"1","key":"9105_CR55","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1080\/21655979.2021.1977102","volume":"12","author":"LB Kwantwi","year":"2021","unstructured":"Kwantwi LB, Wang S, Zhang W, Peng W, Cai Z, Sheng Y et al (2021) Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer. Bioengineered 12(1):6996\u20137006. https:\/\/doi.org\/10.1080\/21655979.2021.1977102","journal-title":"Bioengineered"},{"issue":"10","key":"9105_CR56","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/2326-6066.Cir-23-0721","volume":"12","author":"T Liu","year":"2024","unstructured":"Liu T, Jin D, Le SB, Chen D, Sebastian M, Riva A et al (2024) Machine learning-directed conversion of glioblastoma cells to dendritic cell-like antigen-presenting cells as cancer immunotherapy. Cancer Immunol Res 12(10):1340\u20131360. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-0721","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"9105_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/biology14050547","volume":"14","author":"H Zhu","year":"2025","unstructured":"Zhu H, Ding Y (2025) Nanobodies: from discovery to AI-driven design. Biology 14(5):547. https:\/\/doi.org\/10.3390\/biology14050547","journal-title":"Biology"},{"key":"9105_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09442-9","author":"K Swanson","year":"2025","unstructured":"Swanson K, Wu W, Bulaong NL, Pak JE, Zou J (2025) The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09442-9","journal-title":"Nature"},{"issue":"1","key":"9105_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2490790","volume":"17","author":"A Buchanan","year":"2025","unstructured":"Buchanan A, Bennett E, Croasdale-Wood R, Evers A, Fennell B, Furtmann N et al (2025) How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience. MAbs 17(1):2490790. https:\/\/doi.org\/10.1080\/19420862.2025.2490790","journal-title":"MAbs"},{"key":"9105_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105366","volume":"116","author":"D Xiao","year":"2021","unstructured":"Xiao D, Luo L, Li J, Wang Z, Liu L, Xie F et al (2021) Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem 116:105366. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105366","journal-title":"Bioorg Chem"},{"issue":"2","key":"9105_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020232","volume":"11","author":"S Sau","year":"2019","unstructured":"Sau S, Petrovici A, Alsaab HO, Bhise K, Iyer AK (2019) PDL-1 antibody drug conjugate for selective chemo-guided immune modulation of cancer. Cancers (Basel) 11(2):232. https:\/\/doi.org\/10.3390\/cancers11020232","journal-title":"Cancers (Basel)"},{"key":"9105_CR62","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ab9f57","author":"Q Pan","year":"2021","unstructured":"Pan Q, Li K, Cheng X, Chen L, Yu Q, Fan H (2021) A photoactivatable antibody-Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy. Biomed Mater. https:\/\/doi.org\/10.1088\/1748-605X\/ab9f57","journal-title":"Biomed Mater"},{"issue":"9","key":"9105_CR63","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1111\/cas.14549","volume":"111","author":"C Zhang","year":"2020","unstructured":"Zhang C, Xiong J, Lan Y, Wu J, Wang C, Huang Z et al (2020) Novel cucurmosin-based immunotoxin targeting programmed cell death 1-ligand 1 with high potency against human tumor in vitro and in vivo. Cancer Sci 111(9):3184\u20133194. https:\/\/doi.org\/10.1111\/cas.14549","journal-title":"Cancer Sci"},{"issue":"2","key":"9105_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbcan.2018.08.002","volume":"1870","author":"SC Chang","year":"2018","unstructured":"Chang SC, Ding JL (2018) Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment. Biochim Biophys Acta Rev Cancer 1870(2):165\u2013175. https:\/\/doi.org\/10.1016\/j.bbcan.2018.08.002","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"9105_CR65","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/0008-5472.Can-23-2664","volume":"84","author":"TA Lee","year":"2024","unstructured":"Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH et al (2024) Post-translational modification of PD-1: potential targets for cancer immunotherapy. Cancer Res 84(6):800\u2013807. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-2664","journal-title":"Cancer Res"},{"key":"9105_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649020","volume":"12","author":"G Song","year":"2021","unstructured":"Song G, Zhang Y, Tian J, Ma J, Yin K, Xu H et al (2021) TRAF6 regulates the immunosuppressive effects of myeloid-derived suppressor cells in tumor-bearing host. Front Immunol 12:649020. https:\/\/doi.org\/10.3389\/fimmu.2021.649020","journal-title":"Front Immunol"},{"key":"9105_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102310","volume":"67","author":"SA Bhat","year":"2022","unstructured":"Bhat SA, Vasi Z, Adhikari R, Gudur A, Ali A, Jiang L et al (2022) Ubiquitin proteasome system in immune regulation and therapeutics. Curr Opin Pharmacol 67:102310. https:\/\/doi.org\/10.1016\/j.coph.2022.102310","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"9105_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.312","volume":"6","author":"SC Chang","year":"2015","unstructured":"Chang SC, Ding JL (2015) SAG-UPS regulates malignant transformation\u2013from chronic inflammation to pro-tumorigenesis to liver cancer. Cell Death Dis 6(10):e1941. https:\/\/doi.org\/10.1038\/cddis.2015.312","journal-title":"Cell Death Dis"},{"issue":"1","key":"9105_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2015.32","volume":"1","author":"SC Chang","year":"2015","unstructured":"Chang SC, Choo WQW, Toh HC, Ding JL (2015) SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma. Cell Death Discov 1(1):15032. https:\/\/doi.org\/10.1038\/cddiscovery.2015.32","journal-title":"Cell Death Discov"},{"issue":"9","key":"9105_CR70","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/cdd.2014.54","volume":"21","author":"SC Chang","year":"2014","unstructured":"Chang SC, Ding JL (2014) Ubiquitination by SAG regulates macrophage survival\/death and immune response during infection. Cell Death Differ 21(9):1388\u20131398. https:\/\/doi.org\/10.1038\/cdd.2014.54","journal-title":"Cell Death Differ"},{"key":"9105_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082210","author":"SC Chang","year":"2020","unstructured":"Chang SC, Hsu W, Su EC, Hung CS, Ding JL (2020) Human FBXL8 is a novel E3 ligase which promotes BRCA metastasis by stimulating pro-tumorigenic cytokines and inhibiting tumor suppressors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12082210","journal-title":"Cancers (Basel)"},{"key":"9105_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122873","author":"SC Chang","year":"2021","unstructured":"Chang SC, Hung CS, Zhang BX, Hsieh TH, Hsu W, Ding JL (2021) A novel signature of CCNF-associated E3 ligases collaborate and counter each other in breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13122873","journal-title":"Cancers (Basel)"},{"issue":"3","key":"9105_CR73","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"3","key":"9105_CR74","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"key":"9105_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216861","volume":"590","author":"L Wang","year":"2024","unstructured":"Wang L, Liu X, Han Y, Tsai HI, Dan Z, Yang P et al (2024) TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma. Cancer Lett 590:216861. https:\/\/doi.org\/10.1016\/j.canlet.2024.216861","journal-title":"Cancer Lett"},{"key":"9105_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/jci160456","author":"X Yu","year":"2023","unstructured":"Yu X, Li W, Liu H, Wang X, Coarfa C, Cheng C et al (2023) PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. https:\/\/doi.org\/10.1172\/jci160456","journal-title":"J Clin Invest"},{"issue":"7","key":"9105_CR77","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.celrep.2019.01.075","volume":"26","author":"S Kumar","year":"2019","unstructured":"Kumar S, Barouch-Bentov R, Xiao F, Schor S, Pu S, Biquand E et al (2019) March8 ubiquitinates the Hepatitis C virus nonstructural 2 protein and mediates viral envelopment. Cell Rep 26(7):1800-1814.e1805. https:\/\/doi.org\/10.1016\/j.celrep.2019.01.075","journal-title":"Cell Rep"},{"issue":"1","key":"9105_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","volume":"7","author":"C-W Li","year":"2016","unstructured":"Li C-W, Lim S-O, Xia W, Lee H-H, Chan L-C, Kuo C-W et al (2016) Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7(1):12632. https:\/\/doi.org\/10.1038\/ncomms12632","journal-title":"Nat Commun"},{"issue":"1","key":"9105_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00552-0","volume":"13","author":"Z Hong","year":"2024","unstructured":"Hong Z, Liu F, Zhang Z (2024) Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets. Exp Hematol Oncol 13(1):91. https:\/\/doi.org\/10.1186\/s40164-024-00552-0","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"9105_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34346-x","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z et al (2022) Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun 13(1):6951. https:\/\/doi.org\/10.1038\/s41467-022-34346-x","journal-title":"Nat Commun"},{"key":"9105_CR81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112674118","author":"S De","year":"2021","unstructured":"De S, Holvey-Bates EG, Mahen K, Willard B, Stark GR (2021) The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2112674118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9105_CR82","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gendis.2022.01.002","volume":"10","author":"P Ding","year":"2023","unstructured":"Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan M et al (2023) Emerging role of ubiquitination\/deubiquitination modification of PD-1\/PD-L1 in cancer immunotherapy. Genes Dis 10(3):848\u2013863. https:\/\/doi.org\/10.1016\/j.gendis.2022.01.002","journal-title":"Genes Dis"},{"issue":"6","key":"9105_CR83","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.6.29","volume":"65","author":"X Ling","year":"2024","unstructured":"Ling X, Xu W, Tang J, Cao Q, Luo G, Chen X et al (2024) The role of ubiquitination and the E3 ligase Nedd4 in regulating corneal epithelial wound healing. Invest Ophthalmol Vis Sci 65(6):29. https:\/\/doi.org\/10.1167\/iovs.65.6.29","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"9105_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-1536-x","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang H, Fu C, Du J, Wang H, He R, Yin X et al (2020) Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res 39(1):29. https:\/\/doi.org\/10.1186\/s13046-020-1536-x","journal-title":"J Exp Clin Cancer Res"},{"key":"9105_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005116","author":"J Liu","year":"2022","unstructured":"Liu J, Wei L, Hu N, Wang D, Ni J, Zhang S et al (2022) FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005116","journal-title":"J Immunother Cancer"},{"issue":"3","key":"9105_CR86","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, Zhang Z, Chen HY, Yao Y, Ke S, Yu K et al (2025) Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol Ther 33(3):1073\u20131090. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.047","journal-title":"Mol Ther"},{"issue":"11","key":"9105_CR87","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.jid.2020.03.950","volume":"140","author":"Y Guo","year":"2020","unstructured":"Guo Y, Zhang X, Zeng W, Zhang J, Cai L, Wu Z et al (2020) TRAF6 activates fibroblasts to cancer-associated fibroblasts through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells. J Invest Dermatol 140(11):2268-2279.e2211. https:\/\/doi.org\/10.1016\/j.jid.2020.03.950","journal-title":"J Invest Dermatol"},{"issue":"1","key":"9105_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29401-6","volume":"13","author":"W Xiong","year":"2022","unstructured":"Xiong W, Gao X, Zhang T, Jiang B, Hu MM, Bu X et al (2022) Usp8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun 13(1):1700. https:\/\/doi.org\/10.1038\/s41467-022-29401-6","journal-title":"Nat Commun"},{"issue":"1","key":"9105_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00612-y","volume":"18","author":"Y Wang","year":"2020","unstructured":"Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S (2020) The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal 18(1):112. https:\/\/doi.org\/10.1186\/s12964-020-00612-y","journal-title":"Cell Commun Signal"},{"issue":"10","key":"9105_CR90","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1016\/j.apsb.2024.08.004","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Huang Y, Yu D, Xu M, Hu H, Zhang Q et al (2024) Demethylzeylasteral induces PD-L1 ubiquitin-proteasome degradation and promotes antitumor immunity via targeting USP22. Acta Pharm Sin B 14(10):4312\u20134328. https:\/\/doi.org\/10.1016\/j.apsb.2024.08.004","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"9105_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40160-2","volume":"13","author":"PC Agu","year":"2023","unstructured":"Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO et al (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 13(1):13398. https:\/\/doi.org\/10.1038\/s41598-023-40160-2","journal-title":"Sci Rep"},{"issue":"6","key":"9105_CR92","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth SA, Dror RO (2018) Molecular dynamics simulation for all. Neuron 99(6):1129\u20131143. https:\/\/doi.org\/10.1016\/j.neuron.2018.08.011","journal-title":"Neuron"},{"key":"9105_CR93","unstructured":"HGNC (2025) MARCHF8 membrane associated ring-CH-type finger 8 [ Homo sapiens (human) ]. In HGNC (ed) The National Center for Biotechnology Information"},{"issue":"10","key":"9105_CR94","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1158\/1541-7786.Mcr-21-0147","volume":"19","author":"G Qian","year":"2021","unstructured":"Qian G, Guo J, Vallega KA, Hu C, Chen Z, Deng Y et al (2021) Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. Mol Cancer Res 19(10):1622\u20131634. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-21-0147","journal-title":"Mol Cancer Res"},{"issue":"5","key":"9105_CR95","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/eji.201243043","volume":"43","author":"M Jahnke","year":"2013","unstructured":"Jahnke M, Trowsdale J, Kelly AP (2013) Ubiquitination of HLA-DO by MARCH family E3 ligases. Eur J Immunol 43(5):1153\u20131161. https:\/\/doi.org\/10.1002\/eji.201243043","journal-title":"Eur J Immunol"},{"issue":"64","key":"9105_CR96","doi-asserted-by":"publisher","first-page":"108238","DOI":"10.18632\/oncotarget.22602","volume":"8","author":"J Fan","year":"2017","unstructured":"Fan J, Tian L, Li M, Huang SH, Zhang J, Zhao B (2017) MARCH8 is associated with poor prognosis in non-small cell lung cancers patients. Oncotarget 8(64):108238\u2013108248. https:\/\/doi.org\/10.18632\/oncotarget.22602","journal-title":"Oncotarget"},{"key":"9105_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1230135","volume":"14","author":"C Feng","year":"2023","unstructured":"Feng C, Zhang L, Chang X, Qin D, Zhang T (2023) Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. Front Immunol 14:1230135. https:\/\/doi.org\/10.3389\/fimmu.2023.1230135","journal-title":"Front Immunol"},{"issue":"1","key":"9105_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115128","volume":"44","author":"G Li","year":"2025","unstructured":"Li G, Wen Z, Xiong S (2025) Microenvironmental \u03b2-TrCP negates amino acid transport to trigger CD8(+) T cell exhaustion in human non-small cell lung cancer. Cell Rep 44(1):115128. https:\/\/doi.org\/10.1016\/j.celrep.2024.115128","journal-title":"Cell Rep"},{"issue":"1","key":"9105_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02161-8","volume":"19","author":"C Shen","year":"2021","unstructured":"Shen C, Zhang Z, Tian Y, Li F, Zhou L, Jiang W et al (2021) Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1\/PD-L1 pathway. BMC Med 19(1):283. https:\/\/doi.org\/10.1186\/s12916-021-02161-8","journal-title":"BMC Med"},{"key":"9105_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155874","volume":"133","author":"Z Shi","year":"2024","unstructured":"Shi Z, Zeng H, Zhao B, Zeng C, Zhang F, Liu Z et al (2024) Sulforaphane reverses the enhanced NSCLC metastasis by regulating the miR-7-5p\/c-Myc\/LDHA axis in the acidic tumor microenvironment. Phytomedicine 133:155874. https:\/\/doi.org\/10.1016\/j.phymed.2024.155874","journal-title":"Phytomedicine"},{"key":"9105_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2023.100353","volume":"15","author":"OA Lobanova","year":"2024","unstructured":"Lobanova OA, Kolesnikova AO, Ponomareva VA, Vekhova KA, Shaginyan AL, Semenova AB et al (2024) Artificial intelligence (AI) for tumor microenvironment (TME) and tumor budding (TB) identification in colorectal cancer (CRC) patients: a systematic review. J Pathol Inform 15:100353. https:\/\/doi.org\/10.1016\/j.jpi.2023.100353","journal-title":"J Pathol Inform"},{"issue":"9","key":"9105_CR102","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ajpath.2023.05.012","volume":"193","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li W, Guo S, Wu Z, Zhang L, Liu Y et al (2023) Fbxo22 mediates the NGF\/TRKA signaling pathway in bone metastases in prostate cancer. Am J Pathol 193(9):1248\u20131266. https:\/\/doi.org\/10.1016\/j.ajpath.2023.05.012","journal-title":"Am J Pathol"},{"key":"9105_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005270","author":"M Dong","year":"2022","unstructured":"Dong M, Qian M, Ruan Z (2022) CUL3\/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005270","journal-title":"J Immunother Cancer"},{"issue":"2","key":"9105_CR104","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41418-022-01097-7","volume":"30","author":"K Gao","year":"2023","unstructured":"Gao K, Shi Q, Gu Y, Yang W, He Y, Lv Z et al (2023) Spop mutations promote tumor immune escape in endometrial cancer via the IRF1\u2013PD-L1 axis. Cell Death Differ 30(2):475\u2013487. https:\/\/doi.org\/10.1038\/s41418-022-01097-7","journal-title":"Cell Death Differ"},{"issue":"21","key":"9105_CR105","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/1078-0432.Ccr-23-1439","volume":"29","author":"C Geng","year":"2023","unstructured":"Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S et al (2023) SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clin Cancer Res 29(21):4464\u20134478. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1439","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9105_CR106","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.Can-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y et al (2022) Fgfr3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res 82(1):114\u2013129. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-2362","journal-title":"Cancer Res"},{"issue":"9","key":"9105_CR107","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s13258-022-01238-9","volume":"44","author":"B Zhong","year":"2022","unstructured":"Zhong B, Zheng J, Wen H, Liao X, Chen X, Rao Y et al (2022) NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells. Genes Genomics 44(9):1071\u20131079. https:\/\/doi.org\/10.1007\/s13258-022-01238-9","journal-title":"Genes Genomics"},{"issue":"1","key":"9105_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K et al (2024) Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther 9(1):176. https:\/\/doi.org\/10.1038\/s41392-024-01868-3","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"9105_CR109","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y et al (2021) In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184(21):5357-5374.e5322. https:\/\/doi.org\/10.1016\/j.cell.2021.09.006","journal-title":"Cell"},{"issue":"1","key":"9105_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00440-z","volume":"12","author":"D Luo","year":"2023","unstructured":"Luo D, Chen M, Li Q, Wang K, Wang K, Li J et al (2023) CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression. Exp Hematol Oncol 12(1):77. https:\/\/doi.org\/10.1186\/s40164-023-00440-z","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"9105_CR111","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41556-020-0495-y","volume":"22","author":"S Singh","year":"2020","unstructured":"Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H et al (2020) Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling. Nat Cell Biol 22(5):591\u2013602. https:\/\/doi.org\/10.1038\/s41556-020-0495-y","journal-title":"Nat Cell Biol"},{"issue":"23","key":"9105_CR112","doi-asserted-by":"publisher","first-page":"24394","DOI":"10.18632\/aging.202293","volume":"12","author":"L Zhong","year":"2020","unstructured":"Zhong L, Zhang Y, Li M, Song Y, Liu D, Yang X et al (2020) E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc. Aging (Albany NY) 12(23):24394\u201324423. https:\/\/doi.org\/10.18632\/aging.202293","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"9105_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188679","volume":"1877","author":"SC Chang","year":"2022","unstructured":"Chang SC, Zhang BX, Ding JL (2022) E2\u2013E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers. Biochim Biophys Acta Rev Cancer 1877(2):188679. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188679","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9105_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01517-z","volume":"20","author":"J Li","year":"2020","unstructured":"Li J, Liu N, Tang L, Yan B, Chen X, Zhang J et al (2020) The relationship between TRAF6 and tumors. Cancer Cell Int 20:429. https:\/\/doi.org\/10.1186\/s12935-020-01517-z","journal-title":"Cancer Cell Int"},{"issue":"12","key":"9105_CR115","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.4049\/jimmunol.2100561","volume":"207","author":"BW Liao","year":"2021","unstructured":"Liao BW, Zhang HY, Du WT, Ran Y, Wang YY, Xu ZS (2021) FAM177A1 inhibits IL-1\u03b2-induced signaling by impairing TRAF6-Ubc13 association. J Immunol 207(12):3090\u20133097. https:\/\/doi.org\/10.4049\/jimmunol.2100561","journal-title":"J Immunol"},{"issue":"2","key":"9105_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112125","volume":"42","author":"TET Mevissen","year":"2023","unstructured":"Mevissen TET, Prasad AV, Walter JC (2023) TRIM21-dependent target protein ubiquitination mediates cell-free Trim-away. Cell Rep 42(2):112125. https:\/\/doi.org\/10.1016\/j.celrep.2023.112125","journal-title":"Cell Rep"},{"key":"9105_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312696","author":"M Feng","year":"2024","unstructured":"Feng M, Cui H, Li S, Li L, Zhou C, Chen L et al (2024) Ubiquitin-activating enzyme E1 (UBA1) as a prognostic biomarker and therapeutic target in breast cancer: insights into immune infiltration and functional implications. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252312696","journal-title":"Int J Mol Sci"},{"key":"9105_CR118","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.csbj.2023.01.021","volume":"21","author":"Y Shu","year":"2023","unstructured":"Shu Y, Hai Y, Cao L, Wu J (2023) Deep-learning based approach to identify substrates of human E3 ubiquitin ligases and deubiquitinases. Comput Struct Biotechnol J 21:1014\u20131021. https:\/\/doi.org\/10.1016\/j.csbj.2023.01.021","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"9105_CR119","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) Protac targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21(3):181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"9105_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X (2024) Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther 9(1):308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x","journal-title":"Signal Transduct Target Ther"},{"issue":"37","key":"9105_CR121","doi-asserted-by":"publisher","first-page":"38371","DOI":"10.1021\/acsomega.3c10183","volume":"9","author":"CL Chou","year":"2024","unstructured":"Chou CL, Lin CT, Kao CT, Lin CC (2024) A novel rational PROTACs design and validation via AI-driven drug design approach. ACS Omega 9(37):38371\u201338384. https:\/\/doi.org\/10.1021\/acsomega.3c10183","journal-title":"ACS Omega"},{"issue":"4","key":"9105_CR122","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s11030-024-11011-7","volume":"29","author":"AS Abouzied","year":"2025","unstructured":"Abouzied AS, Alshammari B, Kari H, Huwaimel B, Alqarni S, Kassab SE (2025) AI-DPAPT: a machine learning framework for predicting PROTAC activity. Mol Divers 29(4):2995\u20133007. https:\/\/doi.org\/10.1007\/s11030-024-11011-7","journal-title":"Mol Divers"},{"key":"9105_CR123","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.omto.2022.10.012","volume":"27","author":"Y Chen","year":"2022","unstructured":"Chen Y, Yang Q, Xu J, Tang L, Zhang Y, Du F et al (2022) PROTACs in gastrointestinal cancers. Mol Ther 27:204\u2013223. https:\/\/doi.org\/10.1016\/j.omto.2022.10.012","journal-title":"Mol Ther"},{"issue":"2","key":"9105_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04566-6","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Pang X, Li L, Zeng Z, Chen M, Zhang S (2022) Ubiquitin-specific proteases in inflammatory bowel disease-related signalling pathway regulation. Cell Death Dis 13(2):139. https:\/\/doi.org\/10.1038\/s41419-022-04566-6","journal-title":"Cell Death Dis"},{"issue":"5","key":"9105_CR125","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41396-021-01119-1","volume":"16","author":"TY Ryu","year":"2022","unstructured":"Ryu TY, Kim K, Han T-S, Lee M-O, Lee J, Choi J et al (2022) Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer. ISME J 16(5):1205\u20131221. https:\/\/doi.org\/10.1038\/s41396-021-01119-1","journal-title":"ISME J"},{"issue":"8","key":"9105_CR126","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.4049\/jimmunol.1701478","volume":"204","author":"M Kathania","year":"2020","unstructured":"Kathania M, Tsakem EL, Theiss AL, Venuprasad K (2020) Gut microbiota contributes to spontaneous colitis in E3 ligase Itch-deficient mice. J Immunol 204(8):2277\u20132284. https:\/\/doi.org\/10.4049\/jimmunol.1701478","journal-title":"J Immunol"},{"issue":"5","key":"9105_CR127","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1002\/cam4.5312","volume":"12","author":"H Zhao","year":"2023","unstructured":"Zhao H, Li D, Liu J, Zhou X, Han J, Wang L et al (2023) Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. Cancer Med 12(5):6325\u20136336. https:\/\/doi.org\/10.1002\/cam4.5312","journal-title":"Cancer Med"},{"issue":"6264","key":"9105_CR128","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM et al (2015) Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"issue":"3","key":"9105_CR129","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","volume":"30","author":"JR Bj\u00f6rk","year":"2024","unstructured":"Bj\u00f6rk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT et al (2024) Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat Med 30(3):785\u2013796. https:\/\/doi.org\/10.1038\/s41591-024-02803-3","journal-title":"Nat Med"},{"issue":"5","key":"9105_CR130","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04018-y","volume":"74","author":"S Liu","year":"2025","unstructured":"Liu S, Liu J, Mei Y, Zhang W (2025) Gut microbiota affects PD-L1 therapy and its mechanism in melanoma. Cancer Immunol Immunother 74(5):169. https:\/\/doi.org\/10.1007\/s00262-025-04018-y","journal-title":"Cancer Immunol Immunother"},{"key":"9105_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1254073","volume":"14","author":"AS Malwe","year":"2023","unstructured":"Malwe AS, Sharma VK (2023) Application of artificial intelligence approaches to predict the metabolism of xenobiotic molecules by human gut microbiome. Front Microbiol 14:1254073. https:\/\/doi.org\/10.3389\/fmicb.2023.1254073","journal-title":"Front Microbiol"},{"issue":"1","key":"9105_CR132","doi-asserted-by":"publisher","first-page":"2374954","DOI":"10.1080\/2162402x.2024.2374954","volume":"13","author":"M Bredon","year":"2024","unstructured":"Bredon M, Danne C, Pham HP, Ruffi\u00e9 P, Bessede A, Rolhion N et al (2024) Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13(1):2374954. https:\/\/doi.org\/10.1080\/2162402x.2024.2374954","journal-title":"Oncoimmunology"},{"issue":"1","key":"9105_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04230-8","volume":"23","author":"Z Shi","year":"2025","unstructured":"Shi Z, Jiang W, Li H, Zhang Y, Xue W, Wang Y et al (2025) Faecalibacterium prausnitzii promotes anti-PD-L1 efficacy in natural killer\/T-cell lymphoma by enhancing antitumor immunity. BMC Med 23(1):387. https:\/\/doi.org\/10.1186\/s12916-025-04230-8","journal-title":"BMC Med"},{"issue":"22","key":"9105_CR134","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1158\/0008-5472.Can-23-0605","volume":"83","author":"Y Gao","year":"2023","unstructured":"Gao Y, Xu P, Sun D, Jiang Y, Lin XL, Han T et al (2023) Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 checkpoint blockade. Cancer Res 83(22):3710\u20133725. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-0605","journal-title":"Cancer Res"},{"issue":"6","key":"9105_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114306","volume":"43","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Huang J, Zhang Y, Hou W, Chen F, Mo YY et al (2024) Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell Rep 43(6):114306. https:\/\/doi.org\/10.1016\/j.celrep.2024.114306","journal-title":"Cell Rep"},{"key":"9105_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00556","volume":"11","author":"HC Ku","year":"2020","unstructured":"Ku HC, Cheng CF (2020) Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer. Front Endocrinol (Lausanne) 11:556. https:\/\/doi.org\/10.3389\/fendo.2020.00556","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6371","key":"9105_CR137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R et al (2018) Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"issue":"6558","key":"9105_CR138","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.abc9113","volume":"373","author":"ME Griffin","year":"2021","unstructured":"Griffin ME, Espinosa J, Becker JL, Luo JD, Carroll TS, Jha JK et al (2021) Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373(6558):1040\u20131046. https:\/\/doi.org\/10.1126\/science.abc9113","journal-title":"Science"},{"issue":"1","key":"9105_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li D, Wu M (2021) Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 6(1):291. https:\/\/doi.org\/10.1038\/s41392-021-00687-0","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"9105_CR140","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","volume":"30","author":"A Gunjur","year":"2024","unstructured":"Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW et al (2024) A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat Med 30(3):797\u2013809. https:\/\/doi.org\/10.1038\/s41591-024-02823-z","journal-title":"Nat Med"},{"key":"9105_CR141","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nutos.2024.12.009","volume":"59","author":"DC Fonseca","year":"2025","unstructured":"Fonseca DC, da Rocha Fernandes G, Waitzberg DL (2025) Artificial intelligence and human microbiome: a brief narrative review. Clin Nutr Open Sci 59:134\u2013142. https:\/\/doi.org\/10.1016\/j.nutos.2024.12.009","journal-title":"Clin Nutr Open Sci"},{"issue":"1","key":"9105_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38605-3","volume":"14","author":"X Xiao","year":"2023","unstructured":"Xiao X, Shi J, He C, Bu X, Sun Y, Gao M et al (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun 14(1):2859. https:\/\/doi.org\/10.1038\/s41467-023-38605-3","journal-title":"Nat Commun"},{"issue":"8","key":"9105_CR143","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA et al (2023) Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase i trial. Nat Med 29(8):2121\u20132132. https:\/\/doi.org\/10.1038\/s41591-023-02453-x","journal-title":"Nat Med"},{"issue":"1","key":"9105_CR144","volume":"13","author":"DB Olawade","year":"2025","unstructured":"Olawade DB, Clement David-Olawade A, Adereni T, Egbon E, Teke J, Boussios S (2025) Integrating AI into cancer immunotherapy\u2014a narrative review of current applications and future directions. Dis Sci 13(1):24","journal-title":"Dis Sci"},{"key":"9105_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fdata.2020.00006","volume":"3","author":"BJ Nartowt","year":"2020","unstructured":"Nartowt BJ, Hart GR, Muhammad W, Liang Y, Stark GF, Deng J (2020) Robust machine learning for colorectal cancer risk prediction and stratification. Front Big Data 3:6. https:\/\/doi.org\/10.3389\/fdata.2020.00006","journal-title":"Front Big Data"},{"issue":"8","key":"9105_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221421","volume":"14","author":"BJ Nartowt","year":"2019","unstructured":"Nartowt BJ, Hart GR, Roffman DA, Llor X, Ali I, Muhammad W et al (2019) Scoring colorectal cancer risk with an artificial neural network based on self-reportable personal health data. PLoS ONE 14(8):e0221421. https:\/\/doi.org\/10.1371\/journal.pone.0221421","journal-title":"PLoS ONE"},{"key":"9105_CR147","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2147\/jmdh.S410301","volume":"16","author":"B Zhang","year":"2023","unstructured":"Zhang B, Shi H, Wang H (2023) Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach. J Multidiscip Healthc 16:1779\u20131791. https:\/\/doi.org\/10.2147\/jmdh.S410301","journal-title":"J Multidiscip Healthc"},{"key":"9105_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.inffus.2023.101882","volume":"99","author":"E Mariotti","year":"2023","unstructured":"Mariotti E, Alonso Moral JM, Gatt A (2023) Exploring the balance between interpretability and performance with carefully designed constrainable neural additive models. Inf Fusion 99:101882. https:\/\/doi.org\/10.1016\/j.inffus.2023.101882","journal-title":"Inf Fusion"},{"issue":"6","key":"9105_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.01.013","volume":"7","author":"RD Riley","year":"2025","unstructured":"Riley RD, Ensor J, Snell KIE, Archer L, Whittle R, Dhiman P et al (2025) Importance of sample size on the quality and utility of AI-based prediction models for healthcare. Lancet Digit Health 7(6):100857. https:\/\/doi.org\/10.1016\/j.landig.2025.01.013","journal-title":"Lancet Digit Health"},{"issue":"1","key":"9105_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-024-01833-2","volume":"15","author":"N Sourlos","year":"2024","unstructured":"Sourlos N, Vliegenthart R, Santinha J, Klontzas ME, Cuocolo R, Huisman M et al (2024) Recommendations for the creation of benchmark datasets for reproducible artificial intelligence in radiology. Insights Imaging 15(1):248. https:\/\/doi.org\/10.1186\/s13244-024-01833-2","journal-title":"Insights Imaging"},{"key":"9105_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ailsci.2025.100135","volume":"8","author":"J Agate","year":"2025","unstructured":"Agate J (2025) Artificial intelligence methods and approaches to improve data quality in healthcare data. Artificial Intelligence in the Life Sciences 8:100135. https:\/\/doi.org\/10.1016\/j.ailsci.2025.100135","journal-title":"Artificial Intelligence in the Life Sciences"},{"key":"9105_CR152","doi-asserted-by":"crossref","unstructured":"Aliferis C, Simon G (2024) Overfitting, underfitting and general model overconfidence and under-performance pitfalls and best practices in machine learning and AI. In: Simon GJ, Aliferis C (eds) Artificial Intelligence and Machine Learning in Health Care and Medical Sciences: Best Practices and Pitfalls (pp. 477\u2013524). Cham (CH): Springer Copyright 2024, The Author(s)","DOI":"10.1007\/978-3-031-39355-6_10"},{"issue":"1","key":"9105_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00858-z","volume":"6","author":"M Mittermaier","year":"2023","unstructured":"Mittermaier M, Raza MM, Kvedar JC (2023) Bias in AI-based models for medical applications: challenges and mitigation strategies. NPJ Digit Med 6(1):113. https:\/\/doi.org\/10.1038\/s41746-023-00858-z","journal-title":"NPJ Digit Med"},{"issue":"6","key":"9105_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2025.101882","volume":"71","author":"PS Aravazhi","year":"2025","unstructured":"Aravazhi PS, Gunasekaran P, Benjamin NZY, Thai A, Chandrasekar KK, Kolanu ND et al (2025) The integration of artificial intelligence into clinical medicine: trends, challenges, and future directions. Dis-a-Mon 71(6):101882. https:\/\/doi.org\/10.1016\/j.disamonth.2025.101882","journal-title":"Dis-a-Mon"},{"issue":"1","key":"9105_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90397-y","volume":"11","author":"D Kauffmann-Guerrero","year":"2021","unstructured":"Kauffmann-Guerrero D, Kahnert K, Kiefl R, Sellmer L, Walter J, Behr J et al (2021) Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Sci Rep 11(1):10919. https:\/\/doi.org\/10.1038\/s41598-021-90397-y","journal-title":"Sci Rep"},{"key":"9105_CR156","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood-2024-207751","volume":"144","author":"YJ Shim","year":"2024","unstructured":"Shim YJ, McCrae KR (2024) Role of interferon-gamma (IFN-\u03b3) signaling in immune checkpoint inhibitor-associated thrombosis: tissue factor upregulation and proinflammatory cytokine signature. Blood 144:3989. https:\/\/doi.org\/10.1182\/blood-2024-207751","journal-title":"Blood"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09105-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T01:48:49Z","timestamp":1760665729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9105"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09105-7","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors concur with the submission. No part of this paper has been published or is being considered for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"91"}}